ClinicalTrials.Veeva

Menu

Expanded Access to ABT-414

AbbVie logo

AbbVie

Status

Conditions

Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis

Treatments

Drug: ABT-414

Study type

Expanded Access

Funder types

Industry

Identifiers

NCT03123952
C19-919 (Other Identifier)
C16-478

Details and patient eligibility

About

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABT-414 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Participant must have epidermal growth factor receptor (EGFR) amplification or EGFRvIII mutation.
  • Health Care Provider (HCP) must have prior clinical trial experience with ABT-414.
  • The participant must not be eligible for an ABT-414 clinical trial.
  • Pediatric participants may be evaluated on a case by case basis.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems